GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Carmell Corp (NAS:CTCX) » Definitions » Short-Term Debt

Carmell (Carmell) Short-Term Debt : $0.73 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Carmell Short-Term Debt?

Carmell's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.73 Mil.

Carmell's quarterly Short-Term Debt declined from Sep. 2023 ($7.33 Mil) to Dec. 2023 ($1.29 Mil) and declined from Dec. 2023 ($1.29 Mil) to Mar. 2024 ($0.73 Mil).

Carmell's annual Short-Term Debt declined from Dec. 2021 ($8.60 Mil) to Dec. 2022 ($2.78 Mil) and declined from Dec. 2022 ($2.78 Mil) to Dec. 2023 ($1.29 Mil).


Carmell Short-Term Debt Historical Data

The historical data trend for Carmell's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmell Short-Term Debt Chart

Carmell Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
8.60 2.78 1.29

Carmell Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only - - 7.33 1.29 0.73

Carmell Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Carmell Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Carmell's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Carmell (Carmell) Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Carmell Corp is a regenerative care company with a focus on using human biomaterials for aesthetic and medical care. Its commercial product is a human amnion allograft that can be used as a structural barrier for wound healing. Carmell's R&D pipeline includes several innovative aesthetic, epithelial and bone products under development.
Executives
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036